imatinib mesylate has been researched along with Active Hyperemia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anan, G; Endo, A; Hirose, T; Ito, H; Kato, T; Kimura, T; Kure, S; Matsuki, T; Mori, T; Nakamura, H; Nakayama, S; Oba-Yabana, I; Ohsaki, Y; Shimada, S; Tajima, R; Takahashi, C; Takahashi, K; Tani, J; Yamakoshi, S | 1 |
1 other study(ies) available for imatinib mesylate and Active Hyperemia
| Article | Year |
|---|---|
Inhibition of platelet-derived growth factor pathway suppresses tubulointerstitial injury in renal congestion.
Topics: Animals; Fibrosis; Humans; Hyperemia; Imatinib Mesylate; Kidney; Kidney Diseases; Male; Platelet-Derived Growth Factor; Rats; Rats, Sprague-Dawley | 2022 |